Ignite Creation Date:
2024-05-06 @ 11:01 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03419247
Status:
WITHDRAWN
Last Update Posted:
2021-04-01
First Post:
2017-12-07
Brief Title:
Molecular Profiling of Advanced Biliary Tract Cancers
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers BTC for Better Treatment Selection A Prospective Study COMPASS B
Status:
WITHDRAWN
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was not activated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study where fresh tumor tissue and blood samples will be collected from patients with advanced biliary tract cancer who will be undergoing 1st line therapy with gemcitabine or fluorouracil 5-FU regimens to see how useful it is to look for changes and characteristics in genes molecules that contain instructions for the development and functioning of the cells and the genes within the tumour to find characteristics that may be useful in choosing treatments for patients in the future
Detailed Description:
Changes mutations in genes have been shown to be an important characteristic in cancers Looking at differences in genes in patients with unresectable or metastatic biliary tract cancer and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None